Advanced search
Publication Cover
Journal of Chemotherapy Volume 27, 2015 - Issue 6
Submit an article Journal homepage
75
Views
1
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system

María Antonia Pérez-MorenoPharmacy Department, Hospital Universitario Virgen del Rocío, Seville, SpainCorrespondence[email protected]
,
Jesús Cotrina-LuquePharmacy Department, Hospital Universitario Virgen del Rocío, Seville, Spain
,
Mercedes Galván-BanqueriPharmacy Department, Hospital Universitario Virgen del Rocío, Seville, Spain
,
Sandra Flores-MorenoPharmacy Department, Hospital Universitario Virgen del Rocío, Seville, Spain
,
Francisco Javier Bautista-PalomaPharmacy Department, Hospital Universitario Virgen del Rocío, Seville, Spain
&
Miguel Ángel Calleja-HernándezPharmacy Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
Pages 371-377 | Published online: 14 May 2015

References

  • Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess. 2013;17:1–278.
  • NSCLC, CPG Lung Cancer, Spanish Group. Available from: http://cancergrace.org/lung/tag/spanish-lung-cancer-group/ (accessed 2014 June 18).
  • DiPiro JT, Talbert RL, Yee GCet al., Pharmacotherapy a pathophysiologic approach. Vol. 132. Eighth Edition. Lenexa: ACCP; 2011; p. 2157–73.
  • American Cancer Society. Guidance on lung cancer screening. Georgia: American Cancer Society; 2001. Available from: http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer (accessed 2014 June 18).
  • Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:677–82.
  • Villanueva-Herraiz S, Ortega-García MP, Camps-Herrero C, Blasco-Segura P. Estudio de utilización de pemetrexed en el cáncer de pulmón no microcítico. Farm Hosp. 2010;34:194–203.
  • Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C. Treatment rationale and study design for a phase III double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer. 2010;10:85.
  • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold Cet al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.
  • Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Yet al., Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 2010;14:47–53.
  • Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Yet al., Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer. Health Technol Assess. 2010;14:33–9.
  • Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone Fet al., Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2010;68:319–31.
  • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel Jet al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.
  • Pemetrexed product information (Alimta®). 2013. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/000564/WC500025611.pdf (Accesed September 11 2013).
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology – small cell lung cancer, 2010. 2010. Available from: www.nccn.org/professionals/physician_gls/default.asp (accessed 2013 September 11).
  • NSCLC Spanish Society of Medical Oncology Guide. 2013. Available from: http://www.seom.org/publicaciones/guias-clinicas/102720-guia-seom-de-cancer-pulmon-no-microcitico#esp (accessed 2013 September 11)..
  • Non squamous – NSCLC guide. Andalusian hospital pharmacotherapy guide. 2010. Informe Genesis 3.0 version; Available from: http://gruposdetrabajo.sefh.es/genesis/genesis/Enlaces/InformesHosp_abc.htm#P (accessed 2014 June 18).
  • Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack Eet al., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–40.
  • Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, et al.Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med. 2010;25:294–300.
  • Álvarez Luna F. Farmacoepidemiología. Estudios de Utilización de Medicamentos. Parte I: Concepto y metodología. Seguim Farmacoter. 2004;2:129–36.
  • Santos-Ramos B, Fernández-Fernández R, Marín-Gil R, Espinosa-Bosch M, Peiró-Moreno S, Pérez-Guerrero Cet al., Use of monoclonal antibodies for metastatic colorectal cancer in the Andalusian public health system. Int J Clin Pharm. 2013;35:550–3.
  • Picaza E, Agustin MJ, Varela I, Alonso V, Idoipe-Tomás A. Estudio retrospectivo de la efectividad y seguridad de pemetrexed en mesotelioma pleural maligno y cáncer de pulmón no microcítico. Atención Farmacéutica. 2008;10(2):73–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.